Adverse drug reaction to methotrexate: Pharmacogenetic origin

Peter R. Przekop, Henry Tulgan, Allison A. Przekop, Michael Glantz

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Recent advances in molecular biology have provided physicians with genetic testing strategies that can be used to predict adverse drug reactions (ADRs). Many ADRs can be linked to single-nucleotide polymorphisms in genes that control aspects of drug disposition. We report a case in which a standard dose of methotrexate resulted in life-threatening mucositis, neutropenia, and thrombocytopenia in a 61-year-old woman. The patient was found to have a genetic anomaly in an enzyme that plays a key role in folate metabolism. Methotrexate is known to deplete folate levels. As data accumulate and genetic testing strategies improve, it should be possible to predict ADRs in individual patients, thereby resulting in better patient care and a reduction in medical expenditures.

Original languageEnglish (US)
Pages (from-to)706-707
Number of pages2
JournalThe Journal of the American Osteopathic Association
Volume106
Issue number12
StatePublished - Dec 2006

Fingerprint

Pharmacogenetics
Drug-Related Side Effects and Adverse Reactions
Methotrexate
Genetic Testing
Folic Acid
Mucositis
Drug and Narcotic Control
Health Expenditures
Neutropenia
Thrombocytopenia
Single Nucleotide Polymorphism
Molecular Biology
Patient Care
Physicians
Enzymes
Genes

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Przekop, Peter R. ; Tulgan, Henry ; Przekop, Allison A. ; Glantz, Michael. / Adverse drug reaction to methotrexate : Pharmacogenetic origin. In: The Journal of the American Osteopathic Association. 2006 ; Vol. 106, No. 12. pp. 706-707.
@article{f16f7b10a0414d59b7975913341db84d,
title = "Adverse drug reaction to methotrexate: Pharmacogenetic origin",
abstract = "Recent advances in molecular biology have provided physicians with genetic testing strategies that can be used to predict adverse drug reactions (ADRs). Many ADRs can be linked to single-nucleotide polymorphisms in genes that control aspects of drug disposition. We report a case in which a standard dose of methotrexate resulted in life-threatening mucositis, neutropenia, and thrombocytopenia in a 61-year-old woman. The patient was found to have a genetic anomaly in an enzyme that plays a key role in folate metabolism. Methotrexate is known to deplete folate levels. As data accumulate and genetic testing strategies improve, it should be possible to predict ADRs in individual patients, thereby resulting in better patient care and a reduction in medical expenditures.",
author = "Przekop, {Peter R.} and Henry Tulgan and Przekop, {Allison A.} and Michael Glantz",
year = "2006",
month = "12",
language = "English (US)",
volume = "106",
pages = "706--707",
journal = "The Journal of the American Osteopathic Association",
issn = "0098-6151",
publisher = "American Osteopathic Association",
number = "12",

}

Adverse drug reaction to methotrexate : Pharmacogenetic origin. / Przekop, Peter R.; Tulgan, Henry; Przekop, Allison A.; Glantz, Michael.

In: The Journal of the American Osteopathic Association, Vol. 106, No. 12, 12.2006, p. 706-707.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adverse drug reaction to methotrexate

T2 - Pharmacogenetic origin

AU - Przekop, Peter R.

AU - Tulgan, Henry

AU - Przekop, Allison A.

AU - Glantz, Michael

PY - 2006/12

Y1 - 2006/12

N2 - Recent advances in molecular biology have provided physicians with genetic testing strategies that can be used to predict adverse drug reactions (ADRs). Many ADRs can be linked to single-nucleotide polymorphisms in genes that control aspects of drug disposition. We report a case in which a standard dose of methotrexate resulted in life-threatening mucositis, neutropenia, and thrombocytopenia in a 61-year-old woman. The patient was found to have a genetic anomaly in an enzyme that plays a key role in folate metabolism. Methotrexate is known to deplete folate levels. As data accumulate and genetic testing strategies improve, it should be possible to predict ADRs in individual patients, thereby resulting in better patient care and a reduction in medical expenditures.

AB - Recent advances in molecular biology have provided physicians with genetic testing strategies that can be used to predict adverse drug reactions (ADRs). Many ADRs can be linked to single-nucleotide polymorphisms in genes that control aspects of drug disposition. We report a case in which a standard dose of methotrexate resulted in life-threatening mucositis, neutropenia, and thrombocytopenia in a 61-year-old woman. The patient was found to have a genetic anomaly in an enzyme that plays a key role in folate metabolism. Methotrexate is known to deplete folate levels. As data accumulate and genetic testing strategies improve, it should be possible to predict ADRs in individual patients, thereby resulting in better patient care and a reduction in medical expenditures.

UR - http://www.scopus.com/inward/record.url?scp=33846449097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846449097&partnerID=8YFLogxK

M3 - Article

C2 - 17242415

AN - SCOPUS:33846449097

VL - 106

SP - 706

EP - 707

JO - The Journal of the American Osteopathic Association

JF - The Journal of the American Osteopathic Association

SN - 0098-6151

IS - 12

ER -